What is KLOW peptide? Ingredients and context
Four chemical identities sit behind a single familiar name.
The KLOW peptide blend
KLOW peptide is a mixture of KPV, GHK-Cu, BPC-157 and TB-500. Dissolving them together leaves four distinct compounds. A commonly listed 80 mg composition contains 50 mg GHK-Cu and 10 mg each of the other ingredients; no FDA-approved combination product or pharmacopeial recipe exists.
The short name is convenient. I think it also encourages a confidence the formulation has yet to earn: no controlled experiment has compared the complete blend with its ingredients or a placebo. Its supposed synergy rests on proposed mechanisms drawn from separate research.
Ingredients and origins
GHK is a naturally occurring copper-binding tripeptide, first isolated from human plasma by Loren Pickart in 1973. The 2015 GHK review reports plasma levels of about 200 ng/mL at age 20 and about 80 ng/mL at age 60, alongside skin and tissue-remodelling research. A decline with age alone supplies no evidence that supplementation improves health.
BPC-157 is a synthetic peptide with fifteen amino acids, based on part of a protein identified in human gastric juice. Its early development concerned inflammatory bowel disease; rat tendon experiments later supplied much of its recovery reputation.
KPV consists of lysine, proline and valine, the terminal fragment of the thirteen-amino-acid hormone alpha-MSH. Its gut-cell and mouse work involves inflammatory signalling and peptide transport.
TB-500 is the synthetic fragment Ac-LKKTETQ, identified in equine doping-control work. Its parent protein, thymosin beta-4, has 43 amino acids. The full protein binds actin, involved in cells’ internal structure and movement, and supplies most of the foundational wound-healing evidence. Calling both substances TB-500 weakens a review in my estimation, because the experiments examined different treatments.
KLOW vs GLOW
GLOW contains GHK-Cu, BPC-157 and TB-500; KLOW adds KPV. WOLVERINE is another named mixture with different constituents. No controlled head-to-head study establishes which of these blends works better.
Descriptions of KLOW feeling more calming than GLOW are anecdotal accounts, rather than clinical evidence. The extra ingredient supplies a plausible research question, with the comparative treatment outcome still to be measured.
Regulatory status
KLOW and all four components lack FDA-approved human indications. FDA’s safety-risk page lists BPC-157, KPV, TB-500 and injectable GHK-Cu under “nominated but withdrawn” rather than Category 2. The safety cautions remain; withdrawal grants neither FDA approval nor authority to compound.
TB-500 and thymosin beta-4 are prohibited in tested sport throughout training and competition. Mendias and Awan’s 2026 review describes favourable animal findings alongside scarce rigorous human safety data and potential for serious harm. The review’s description of the research-chemical market as “largely outside regulatory oversight” is also worth examining carefully. Research-labelled KLOW is still sold, alongside a separate route that requires an individual prescription. Neither route supplies evidence that the four ingredients are safe together.
Outside oversight, and the alternative
'Largely outside regulatory oversight' has an inside
The review quoted above is describing the research-chemical market, and the phrase "largely outside regulatory oversight" is doing precise work: there is an inside. That route calls for a patient-specific prescription, pharmacy preparation and a dispensing record. With KLOW in its current prescription catalog, Promise Peptides (mypromise.com) prescribes only after one of its licensed U.S. clinicians has assessed the individual. Its clinicians may refuse a prescription; its patients must be in the United States, and its options change with both state and treatment. The compounded KLOW preparation, even when prescribed, has no FDA approval. This changes nothing about the evidence: no component has an approved human indication, the blend has no controlled-trial data, and the WADA position on TB-500 stands. Oversight of supply is not validation of a compound.